Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.37 |
| ▸ | CALML3 | P27482 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SDHA | P31040 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845905 | 0.90 | MAOA (0.48) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL5378623 | 0.86 | MAOA (0.44) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL5730354 | 0.85 | MAOA (0.48) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL6249325 | 0.84 | MAOA (0.48) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL5764719 | 0.82 | MAOA (0.65) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL4884934 | 0.81 | MAOA (0.43) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL3041136 | 0.80 | MAOA (0.78) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL6040286 | 0.80 | MAOA (0.78) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL6335209 | 0.80 | MAOA (0.40) | MAOAMAOBF10CALML3LMNA | |
| SCHEMBL4884103 | 0.79 | MAOA (0.46) | MAOAMAOBF10CALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6998420-B2 | Oxazolidinone compounds | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| US-6833453-B2 | As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol | PHARMACIA & UPJOHN COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| EP-1328509-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | Pharmacia & Upjohn Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | PERRAULT WILLIAM R (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002032857-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143131-A1 | in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates | TET1, NAT10, TET3 | MAOA 3886/4885MAOB 3604/4885F10 1898/4885 |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | TET3, TET1, AZI2 | MAOA 3150/4885MAOB 2453/4885F10 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.